Interferon Regulatory Factor-1 and -2 Expression in Human Melanoma Specimens
Abstract
Background: Interferon regulatory factor (IRF)-1 and IRF-2 are nuclear transcription factors that respond to interferon-γ. IRF-1 acts as the effector arm of the interferon-γresponse in tumor cells, whereas IRF-2 binds to the same DNA consensus sequence and opposes IRF-1 activity. This effect is intact in human and murine tumor models, including melanomas; previous work in our laboratory demonstrated the tumor-suppressing activity of IRF-1 expression in in vivo models and the opposing effect of IRF-2. The expression of IRF-1 and -2 in human solid tumors had not been previously investigated.
Methods: Formalin-fixed, paraffin-embedded, archival tissue specimens from 38 human melanomas were obtained and stained with polyclonal anti-IRF-1 and anti-IRF-2 antibodies, using an avidin-biotin-peroxidase complex technique with epitope retrieval.
Results: Twenty-nine specimens showed granular cytoplasmic staining with the anti-IRF-1 or anti-IRF-2 antibodies. IRF-1 staining was correlated with less advanced disease. Superficial spreading and in situ lesions exhibited more frequent IRF-1 staining, compared with nodular or metastatic disease. Only more advanced lesions showed neither IRF-1 nor IRF-2 staining.
Conclusions: Immunohistochemical staining of archival tissue identified IRF-1 and -2 in human melanomas; this had not been previously demonstrated. IRF-1 staining was correlated with the morphologic characteristics of less advanced disease. Tumor-suppressing effects of IRF-1 may account for the less aggressive biologic features of IRF-1-expressing melanomas, as we would predict from the experimental data.
Key Words
Interferon-γ—Human melanoma—Interferon regulatory factor-1 and -2Preview
Unable to display preview. Download preview PDF.
REFERENCES
- 1.Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-gamma receptors. Immunity 1994;1:447–456.CrossRefPubMedGoogle Scholar
- 2.Doherty GM, Tsung K, McCluskey B, Norton JA. Endogenous interferon gamma acts directly on tumor cells in vivo to suppress growth. J Surg Res 1996;64:68–74.Google Scholar
- 3.Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.Google Scholar
- 4.Geller DA, Nguyen D, Shapiro RA, et al. Cytokine induction of interferon regulatory factor-1 in hepatocytes. Surgery 1993;114:235–242.Google Scholar
- 5.Pine R. Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection. J Virol 1992;66:4470–4478.Google Scholar
- 6.Coccia EM, Marziali G, Stellacci E, et al. Cells resistant to interferon-beta respond to interferon-gamma via the STAT1-IRF-1 pathway. Virology 1995;211:11–122.Google Scholar
- 7.Kamijo R, Harada H, Matsuyama T, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994;263:1612–1615.Google Scholar
- 8.Martin E, Nathan C, Xie Q-W. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med 1994;180:977–984Google Scholar
- 9.Briken V, Ruffner H, Schultz U, et al. Interferon regulatory factor 1 is required for mouse gbp gene activation by gamma interferon. Mol Cell Biol 1995;15:975–982.Google Scholar
- 10.Chang C-H, Hammer J, Loh JE, Fodor WL, Flavell RA. The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1). Immunogenetics 1992;35:378–384.Google Scholar
- 11.Lim SP, Hui KM. Characterization of a novel IRF-1 deficient mutant cell line. Immunogenetics 1994;39:168–177.Google Scholar
- 12.Reis LFL, Harada H, Wolchok JD, Taniguchi T, Vilcek J. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. EMBO J 1992;11:185–193.Google Scholar
- 13.Hobart M, Ramassar V, Goes N, Urmson J, Halloran PF. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J Immunol 1997;158:4260–4269.Google Scholar
- 14.Hobart M, Ramassar V, Goes N, Urmson J, Halloran PF. The induction of class I and II major histocompatibility complex by allogeneic stimulation is dependent on the transcription factor interferon regulatory factor 1 (IRF-1). Transplantation 1996;62:1895–1901.Google Scholar
- 15.Yim JH, Wu SJ, Casey MJ, Norton JA, Doherty GM. Interferon regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice. J Immunol 1997;158:1284–1292.Google Scholar
- 16.Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, Taniguchi T. Absence of the type 1 IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 1990;63:303–312.Google Scholar
- 17.Fujita T, Kimura Y, Miyamoto M, Barsoumian EL, Taniguchi T. Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature 1989;337:270–272.CrossRefPubMedGoogle Scholar
- 18.Harada H, Kitagawa M, Tanaka N, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971–974.Google Scholar
- 19.Doherty GM, McCluskey B, Tsung K, Norton JA. Correlation of interferon regulatory factors 1 and 2 (IRF-1 and -2): expression and murine tumor growth in the presence of interferon-gamma. Surg Forum 1995;46:544–546.Google Scholar
- 20.Yim JH, Wu SJ, Lowney JK, Vander Velde TL, Doherty GM. Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous interferon-γ. J Interferon Cytokine Res (in press).Google Scholar
- 21.Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968–70.Google Scholar
- 22.Tamura G, Ogasawara S, Nishizuka S, et al. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996;56:612–5.Google Scholar
- 23.Ogasawara S, Tamura G, Maesawa C, et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 1996;110:52–7.Google Scholar